KR20150106478A - Extract of Black raspberry containing lactic acid bacterium for immunological enhancement and improving climacteric symptoms - Google Patents
Extract of Black raspberry containing lactic acid bacterium for immunological enhancement and improving climacteric symptoms Download PDFInfo
- Publication number
- KR20150106478A KR20150106478A KR1020140028276A KR20140028276A KR20150106478A KR 20150106478 A KR20150106478 A KR 20150106478A KR 1020140028276 A KR1020140028276 A KR 1020140028276A KR 20140028276 A KR20140028276 A KR 20140028276A KR 20150106478 A KR20150106478 A KR 20150106478A
- Authority
- KR
- South Korea
- Prior art keywords
- lactic acid
- oil
- bacterium
- present
- improving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 72
- 241000894006 Bacteria Species 0.000 title claims abstract description 64
- 239000004310 lactic acid Substances 0.000 title claims abstract description 36
- 235000014655 lactic acid Nutrition 0.000 title claims abstract description 36
- 206010027304 Menopausal symptoms Diseases 0.000 title claims abstract description 26
- 239000000284 extract Substances 0.000 title description 4
- 244000111388 Rubus occidentalis Species 0.000 title description 2
- 235000003942 Rubus occidentalis Nutrition 0.000 title description 2
- 230000001900 immune effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 36
- 235000013305 food Nutrition 0.000 claims abstract description 23
- 239000004480 active ingredient Substances 0.000 claims abstract description 16
- 208000024891 symptom Diseases 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims description 32
- 235000017848 Rubus fruticosus Nutrition 0.000 claims description 12
- 238000003825 pressing Methods 0.000 claims description 10
- 241001092459 Rubus Species 0.000 claims description 9
- 230000006872 improvement Effects 0.000 claims description 4
- 241000131482 Bifidobacterium sp. Species 0.000 claims description 3
- 241000194033 Enterococcus Species 0.000 claims description 3
- 241001495410 Enterococcus sp. Species 0.000 claims description 3
- 241000186610 Lactobacillus sp. Species 0.000 claims description 3
- 241000178948 Lactococcus sp. Species 0.000 claims description 3
- 241001627205 Leuconostoc sp. Species 0.000 claims description 3
- 241000194022 Streptococcus sp. Species 0.000 claims description 3
- 244000172730 Rubus fruticosus Species 0.000 claims 4
- 240000001046 Lactobacillus acidophilus Species 0.000 claims 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims 2
- 230000002498 deadly effect Effects 0.000 claims 2
- 239000002035 hexane extract Substances 0.000 claims 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims 2
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 claims 1
- 229960000794 baclofen Drugs 0.000 claims 1
- 230000036039 immunity Effects 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 8
- 230000002708 enhancing effect Effects 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 239000000047 product Substances 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 4
- 230000000968 intestinal effect Effects 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 239000006227 byproduct Substances 0.000 abstract description 2
- 210000000987 immune system Anatomy 0.000 abstract description 2
- 239000003921 oil Substances 0.000 description 36
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 8
- 235000013376 functional food Nutrition 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000000638 solvent extraction Methods 0.000 description 4
- 229960003604 testosterone Drugs 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-3',4',5,7-Tetrahydroxy-2,3-trans-flavan-3-ol Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 3
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000001727 glucose Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000009245 menopause Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 235000005875 quercetin Nutrition 0.000 description 3
- 229960001285 quercetin Drugs 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229930013783 (-)-epicatechin Natural products 0.000 description 2
- 235000007355 (-)-epicatechin Nutrition 0.000 description 2
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Chinese gallotannin Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000017657 Menopausal disease Diseases 0.000 description 2
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 108010013639 Peptidoglycan Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- LJSQFQKUNVCTIA-UHFFFAOYSA-N diethyl sulfide Chemical compound CCSCC LJSQFQKUNVCTIA-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229920001968 ellagitannin Polymers 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 238000007731 hot pressing Methods 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 229930013915 (+)-catechin Natural products 0.000 description 1
- 235000007219 (+)-catechin Nutrition 0.000 description 1
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- JMGCAHRKIVCLFW-UHFFFAOYSA-N 1-O-Galloylcastalagin Natural products Oc1cc(cc(O)c1O)C(=O)OC2C3OC(=O)c4c2c(O)c(O)c(O)c4c5c(O)c(O)c(O)c6c5C(=O)OC3C7OC(=O)c8cc(O)c(O)c(O)c8c9c(O)c(O)c(O)cc9C(=O)OCC7OC(=O)c%10cc(O)c(O)c(O)c6%10 JMGCAHRKIVCLFW-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- SQCZQTSHSZLZIQ-UHFFFAOYSA-N 1-chloropentane Chemical compound CCCCCCl SQCZQTSHSZLZIQ-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- JYDJORPVCNGOGY-UHFFFAOYSA-N C=CCCC.CCCCCCCCCC Chemical compound C=CCCC.CCCCCCCCCC JYDJORPVCNGOGY-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- OEIJRRGCTVHYTH-UHFFFAOYSA-N Favan-3-ol Chemical compound OC1CC2=CC=CC=C2OC1C1=CC=CC=C1 OEIJRRGCTVHYTH-UHFFFAOYSA-N 0.000 description 1
- 206010016825 Flushing Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 206010024870 Loss of libido Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- XFZJEEAOWLFHDH-RBYKNZBFSA-N Procyanidin B4 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@@H]1c1c(O)cc(O)c3c1O[C@H]([C@@H](O)C3)c1cc(O)c(O)cc1)c(O)cc(O)c2 XFZJEEAOWLFHDH-RBYKNZBFSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 241001618264 Rubus coreanus Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- JMGCAHRKIVCLFW-CNWXVVPTSA-N ellagitannin Chemical compound OC1=C(O)C(O)=CC(C(=O)O[C@H]2C3=C4C(=O)O[C@@H]2[C@@H]2[C@@H]5OC(=O)C6=CC(O)=C(O)C(O)=C6C6=C(O)C(O)=C(O)C=C6C(=O)OC[C@H]5OC(=O)C5=CC(O)=C(O)C(O)=C5C=5C(O)=C(O)C(O)=C(C=5C(=O)O2)C4=C(O)C(O)=C3O)=C1 JMGCAHRKIVCLFW-CNWXVVPTSA-N 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930182497 flavan-3-ol Natural products 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- -1 fluoroalkane Chemical compound 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 229920002824 gallotannin Polymers 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- ULYZAYCEDJDHCC-UHFFFAOYSA-N isopropyl chloride Chemical compound CC(C)Cl ULYZAYCEDJDHCC-UHFFFAOYSA-N 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014972 male genitalia development Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940078552 o-xylene Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- XFZJEEAOWLFHDH-VUGKQVTMSA-N procyanidin B4 Chemical compound C1([C@@H]2[C@@H](O)[C@@H](C3=C(O)C=C(O)C=C3O2)C=2C(O)=CC(O)=C3C[C@H]([C@H](OC3=2)C=2C=C(O)C(O)=CC=2)O)=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-VUGKQVTMSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002294 pubertal effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 복분자유 및 유산균을 유효성분으로 포함하는 면역증강 및 갱년기증상 개선용 조성물을 제공한다. 본 발명에 따른 복분자유 및 유산균을 포함하는 복합 조성물은 위장내 유익균을 증가시킬뿐만 아니라, 면역증강 및 갱년기증상 개선의 효과를 제공한다. 또한, 버려지는 농식품 부산물인 복분자박을 이용하여 추출한 복분자유를 활용하기 때문에 식품소재로서 안전할 뿐만 아니라 제조상 경제적인 이점이 있다.The present invention provides a composition for improving immunity and improving menopausal symptoms comprising bacterium oil and lactic acid bacteria as an active ingredient. The complex composition comprising the bacterium oil and the lactic acid bacterium according to the present invention not only increases the intestinal beneficial bacteria but also provides the effect of enhancing the immune system and improving the symptoms of menopausal symptoms. In addition, since it uses bokbunja oil extracted from bokbunjae which is an abandoned agricultural product byproduct, it is safe as a food material and has an economical advantage in manufacturing.
Description
본 발명은 복분자유 및 유산균을 유효성분으로 포함하는 면역증강 및 갱년기증상 개선용 조성물에 관한 것이다.The present invention relates to a composition for improving immunity and improving menopausal symptoms comprising bacterium oil and lactic acid bacteria as an active ingredient.
복분자(black raspberry)는 장미과(Rosaceae)에 속하는 다년생의 낙엽 관목인 복분자 딸기나무(Rubus coreanus Miq.)의 열매다. 중국이 원산지로 알려져 있으며 우리나라에는 제주도 및 남부지역이 주요산지로 알려져 있다. 복분자는 초여름에 검붉은 열매를 수확하여 식용으로 활용하고 있으며 예로부터 한방에서는 강장제, 강정제 및 간을 보호하는 요약으로 귀한 약재로 알려져 왔으며, 신체 허약, 양위, 유정 및 유뇨 등에 실용되는 소재이다[Park, Y. S., Chang, H. G., J. Korean Soc. Agr. Chem. Biotechnol. 46: 367-375, 2003; Heo, J., Dongyeubogam. Publications on oreiental medicine written]. 복분자에 함유된 성분 중, 줄기에는 플라반 3-올(flavan 3-ol)인 (-)-에피카테킨((-)-epicatechin), (+)-카테킨( (+)-catechine), 그리고 프로시아니딘 B-4(procyanidin B-4)가 있다고 알려져 있으며, 잎에는 캠프레롤(kaempferol), 쿼세틴(quercetin), 쿼세틴 3-O-β-D-글루쿠로노이드(quercetin 3-O-β-D-glucuronoide), 엘라그산(ellagic acid), 및 산구인 H-5(sanguin H-5) 등이 존재함이 알려져 있다. 또한 복분자 열매로부터는 퀘세틴 및 다양한 페놀 화합물의 존재가 보고되어 있다[Yoon, I., Cho, J. Y., Kuk, J. H., Wee, J. H., Jang, M. Y., Ahn, T. H., Park, K. H., Korean J. Food Sci. Technol., 34:898-904, 2002]. 아울러 미성숙과에도 다양한 페놀 화합물들이 존재하는 것으로 알려져 있은데, 대표적으로 갈로탄닌(gallotannin), 엘라기탄닌( ellagitannin), 갈산(gallic acid), 및 2,3-(S)-HHDP-D-글루코피라노사이드, 산구인 H-4 및 H-6 존재가 확인되었다 [Pang, G.C., Kom, M.S., Lee, M.W., Korean J. Pharmacogn. 27:366-370, 1996].Black raspberry is the fruit of Rubus coreanus Miq., A perennial deciduous shrub belonging to Rosaceae. China is known as a country of origin and Jeju and southern regions are known to be the major producing regions in Korea. Bokbunja is harvested in early summer and used for food. It has been known as a valuable medicinal product for protecting tannins, gonjeongje, and liver in the past, and it is a practical material for physical weakness, , YS, Chang, HG, J. Korean Soc. Agr. Chem. Biotechnol. 46: 367-375, 2003; Heo, J., Dongyeubogam. Publications on oreiental medicine written]. Among the components contained in the bokbunja, the stem contains flavan 3-ol (-) - epicatechin ((-) - epicatechin), (+) - catechin 4 (procyanidin B-4). Leaves are known to contain kaempferol, quercetin, quercetin 3-O-β-D-glucuronoide ), Ellagic acid, and acid globulin H-5 (sanguin H-5). In addition, the presence of quercetin and various phenol compounds from bokbunja fruit has been reported [Yoon, I., Cho, JY, JH, Wee, JH, Jang, MY, Ahn, TH, Park, Food Sci. Technol., 34: 898-904, 2002). In addition, various phenolic compounds are known to exist in the immature stage, and gallotannin, ellagitannin, gallic acid, and 2,3- (S) -HHDP-D-glue The presence of caprylanoside, acid H-4 and H-6 was confirmed (Pang, GC, Kom, MS, Lee, MW, Korean J. Pharmacogn. 27: 366-370, 1996].
본 발명자들은 복분자에 대한 계속적인 연구를 통해 일반적으로 식품에 사용되고 있는 복분자 열매의 열수추출물이 아닌 복분자씨에서 추출한 복분자유가 공액리놀레산을 비롯한 오메가-3, 오메가-6, 엘라지탄닌류(ellagitannins), 엘라그산(ellagic acid), 팔미트산, 스테아르산 및 올레산 등의 활성 성분을 함유하고 있어 기능성 성분으로 활용될 수 있다는 사실을 밝힌 바 있다(한국 특허등록번호 제1168169호). 계속적으로, 본 발명자들은 복분자유의 다양한 생리활성 조절 기능에 대해 연구하였으며, 그 결과 복분자유의 면역증강 및 갱년기증상 개선 활성을 발견하고 본 발명을 완성하였다. The present inventors have conducted continuous studies on bokbunja, and found that bokbunja oil extracted from bokbunja seed, which is not a hydrothermal extract of bokbunja fruit generally used for food, has a high content of omega-3, omega-6, ellagitannins, Stearic acid, oleic acid, and the like, and thus it can be used as a functional ingredient (Korean Patent Registration No. 1168169). Continuously, the present inventors have studied various physiological activity regulating functions of brambled oil, and as a result, they found immune enhancement of brambled oil and improving activity of menopausal symptoms and completed the present invention.
본 발명은 면역증강 및 갱년기증상 개선을 위해 사용할 수 있는 복분자유 및 유산균을 유효성분으로 포함하는 복합 조성물을 제공하고자 한다. The present invention is to provide a composite composition comprising bacterium oil and lactic acid bacteria, which can be used for improving immunity and improving menopausal symptoms, as an active ingredient.
본 발명자들은 복분자유의 다양한 생리활성 조절기능을 연구하면서 면역증강 또는 갱년기증상 개선을 위해 사용할 수 있는 복합 소재를 개발하고자 노력하였다. 그 결과 복분자유와 유산균의 복합 조성물이 우수한 면역증강 효능이 있다는 것을 규명함으로써 본 발명을 완성하게 되었다. The present inventors have studied various physiological activity control functions of brambly oil and have sought to develop a composite material that can be used for improving immunity or improving menopausal symptoms. As a result, the present inventors have completed the present invention by confirming that the complex composition of bokbunja oil and lactic acid bacterium has excellent immunity enhancing effect.
본 발명은 복분자유 및 유산균을 포함하는 면역증강 및 갱년기증상 개선용 조성물을 제공한다.The present invention provides a composition for improving immunity and improving menopausal symptoms comprising bacterium oil and lactic acid bacteria.
본 발명에 있어서, 면역증강이라 함은 일반적으로 일컫는 면역력 증진을 의미하며, 보다 구체적으로는 인체의 대식세포, 보체 등을 활성화하고 각종 면역 관련 사이토카인의 발현을 유도하는 것을 포함하는 개념이다. In the present invention, the term " immune enhancement " refers to a generally referred to as immunity enhancement. More specifically, it is a concept including activation of macrophages, complement, etc. of the human body and induction of expression of various immune related cytokines.
한편, 갱년기(climacteric)란 내분비 증후군의 일종으로 호르몬의 변화로 인해 생리적 기능 및 성기능이 감소 내지 소실되는 과도기를 말한다. 여성의 경우, 갱년기의 한 과정으로 난소기능의 정지 후에 일어나는 생리의 영구적인 정지인 폐경(menopause)이 오게 된다. 폐경기에는 에스트로겐 생성의 감소, 난포자극호르몬(follicular stimulating hormone, FSH) 및 황체화호르몬(luteininzing hormone, LH)의 상승 등 호르몬의 변화에 따라 급만성 증상이 나타날 수 있다. 여성 갱년기 장애의 초기증상으로 열성홍조(hot flush), 야간 발한(night sweat) 등의 혈관 운동성 증상(vasomotor symptom)과 불안감, 집중력 감퇴, 우울증 등의 심리적 증상(psychological symptom)이 나타날 수 있으며, 폐경 수년 내에 나타나는 비뇨생식계 및 표피증상이, 폐경 수년 후에는 골다공증, 심장혈관 및 뇌혈관 질환 등이 있을 수 있다. 또한, 남성의 경우에는 테스토스테론의 분비 변화에 따른 갱년기 증상을 겪게 된다. 테스토스테론은 남성 생식기의 발달, 골격이나 근육의 발달, 성욕·성 충동의 항진 및 뇌나 정신면의 활력 항진에도 영향을 미치는 것으로 여겨진다. 혈중 테스토스테론은 강한 스트레스를 받았을 경우에 그 농도가 저하된다는 것이 알려져 있다. 혈중 테스토스테론이 저하되면, 남성 갱년기 장애나 사춘기 지발증(遲發症) 등의 질병을 일으킨다. 남성 갱년기 장애가 되면, 다양한 증상 (예를 들어, 낙담, 우울, 초조, 불안, 신경 과민, 생기 소실, 피로감, 관절염, 근육염, 근력 저하, 발한, 안면 홍조, 수면 장애, 기억력 저하, 집중력 저하, 육체적 소모감, 성욕 저하, 발기 장애, 사정감 소실 등) 이 강하게 발현된다. 본 발명에서 갱년기증상의 개선이라 함은 이와 같은 여성 갱년기증상 또는 남성 갱년기증상의 개선을 모두 포함한다.On the other hand, climacteric (climacteric) is a type of endocrine syndrome, which means that the physiological function and sexual function are reduced or lost due to hormonal changes. In women, menopause, a permanent process of menstruation that occurs after cessation of ovarian function, is a process of menopause. Postmenopausal women may have acute chronic symptoms due to changes in hormones, such as decreased estrogen production, follicular stimulating hormone (FSH), and elevated luteininzing hormone (LH). Early symptoms of female menopausal symptoms may include psychological symptoms such as vasomotor symptoms such as hot flush and night sweat, anxiety, loss of concentration, depression, Urogenital and epidermal manifestations that occur within a few years may be osteoporosis, cardiovascular and cerebrovascular disease after years of menopause. Men also experience menopausal symptoms due to changes in secretion of testosterone. Testosterone is thought to affect male genital development, skeletal or muscular development, sexual arousal, agitation, and hyperactivity in the brain and mental faculties. It is known that serum testosterone decreases its concentration when subjected to strong stress. When serum testosterone is lowered, it causes diseases such as male menopausal disorder or pubertal disease (遲发 症). Men's menopausal disorders can result in a variety of symptoms (for example, depression, depression, anxiety, anxiety, nervousness, loss of vigor, fatigue, arthritis, myositis, muscle weakness, sweating, facial flushing, sleep disturbances, Loss of appetite, loss of libido, erectile dysfunction, loss of appetite) are strongly expressed. In the present invention, improvement of menopausal symptoms includes improvement of such female menopausal symptoms or male menopausal symptoms.
본 발명의 일 실시예에서는, 복분자유 및 유산균이 종래에 알려진 유산균의 면역증강 효과에 비해 훨씬 증가된 면역증강 효과를 나타내며, 뿐만아니라 여성 및 남성의 갱년기증상을 개선할 수 있는 효능을 갖는 것을 보여준다. 따라서, 복분자유 및 유산균의 복합 조성물은 면역증강 및 갱년기증강 개선용 조성물의 유효성분으로서 사용될 수 있다. In one embodiment of the present invention, the bacterium oil and the lactic acid bacterium exhibit a much improved immune enhancing effect as compared with the immunopotentiating effect of the conventionally known lactic acid bacteria, and have the effect of improving the menopausal symptoms of women and men as well . Therefore, a complex composition of bacterium oil and lactic acid bacteria can be used as an active ingredient of a composition for improving immunity and improving menopausal symptoms.
본 발명에 있어서, 상기 복분자유는 공지의 방법을 통해 제조되는 복분자 씨의 기름 성분을 모두 포함한다. In the present invention, the bramble oil includes all of the oil components of the bramble seeds produced by a known method.
복분자유를 제조하는 공지의 방법으로는 냉압착법, 온압착법, 저온압착법 및 용매 추출법 등을 이용할 수 있다. Known methods for producing bokromatic oil include a cold pressing method, a hot pressing method, a low temperature pressing method, and a solvent extraction method.
본 발명에서, 냉압착법이란 열을 가할 때 흘러나오는 씨를 열처리 하지 않고 바로 압착하여 기름을 얻는 방법으로 열을 가할 때 색소, 방향, 및 검(Gum)질 등이 기름 안에 흘러 나와 기름의 빛깔이 진하고 맛이 나쁠 때가 있으므로 좋은 기름을 얻기 위해 파쇄한 것을 열처리하지 않고 곧 압착하는 방법이며, 온압착법이란, 100 ~ 250 ℃의 고온에서 볶은 후 쪄서 압착하는 방법이고, 저온압착법이란, 43 ℃ 이하로 압착하여 기름을 짜내는 방법이다. 또한, 상기 용매 추출법은 n-헥산 등의 용매를 사용하여 추출하는 방법이다.In the present invention, the cold pressing method is a method of obtaining oil by directly pressing the seed which is flowing when heat is applied without heat treatment, whereby coloring matter, direction and gum quality are discharged into the oil when heat is applied, The hot pressing method is a method of pressing at a high temperature of 100 to 250 DEG C and then pressing it. The low temperature pressing method is a method of pressing at 43 DEG C Or less, and squeeze the oil. The solvent extraction method is a method of extracting with a solvent such as n-hexane.
예를 들어, 본 발명은 복분자씨를 바람직하게는 43℃ 내지 200 ℃에서 60분 내지 120분 동안, 더욱 바람직하게는 120℃ 내지 190℃에서 60분 내지 120분 동안 착유하여 복분자유를 수득할 수 있다. For example, the present invention is able to obtain bramble oil by milking brambly seeds preferably at 43 ° C to 200 ° C for 60 to 120 minutes, more preferably at 120 to 190 ° C for 60 to 120 minutes .
본 발명에 있어서, 상기 용매추출법은 물, 유기용매 또는 이들의 혼합물을 추출 용매로서 이용하여 복분자씨로부터 추출물을 제조하는 방법을 말한다. 이 때 사용되는 유기용매의 종류나 물과 유기용매의 혼합 비율은 특별히 제한되지 않는다. In the present invention, the solvent extraction method refers to a method of producing an extract from bramblymus seeds using water, an organic solvent, or a mixture thereof as an extraction solvent. The kind of the organic solvent used at this time and the mixing ratio of water and the organic solvent are not particularly limited.
예를 들어, 상기 유기용매는 저급 알코올, 헥산, 아세톤, 에틸 아세테이트, 클로로포름, 및 디에틸에테르로 이루어진 군으로부터 선택된 하나 이상의 용매일 수 있다. 상기 저급 알코올은 탄소수 1 내지 6의 알코올일 수 있다. 예를 들어, 저급 알코올로는 메탄올, 에탄올, 프로판올, 부탄올, 노말-프로판올, 이소-프로판올, 노말-부탄올, 1-펜탄올, 2-부톡시에탄올 또는 에틸렌글리콜 등을 이용할 수 있다. 유기용매는 이 외에도 아세트산, DMFO(dimethyl-formamide), DMSO(dimethyl sulfoxide) 등의 극성 용매, 아세토나이트릴, 에틸 아세테이트, 메틸 아세테이트, 플루오로알칸, 펜탄, 2,2,4-트리메틸펜탄, 데칸, 사이클로헥산, 사이클로펜탄, 디이소부틸렌, 1-펜텐, 1-클로로부탄, 1-클로로펜탄, o-자일렌, 디이소프로필 에테르, 2-클로로프로판, 톨루엔, 1-클로로프로판, 클로로벤젠, 벤젠, 디에틸 에테르, 디에틸 설파이드, 클로로포름, 디클로로메탄, 1,2-디클로로에탄, 어닐린, 디에틸아민, 에테르, 사염화탄소 및 THF(Tetrahydrofuran) 등의 비극성 용매를 사용할 수도 있다.For example, the organic solvent may be one or more solvents selected from the group consisting of lower alcohols, hexane, acetone, ethyl acetate, chloroform, and diethyl ether. The lower alcohol may be an alcohol having 1 to 6 carbon atoms. For example, as the lower alcohol, methanol, ethanol, propanol, butanol, n-propanol, iso-propanol, n-butanol, 1-pentanol, 2-butoxyethanol or ethylene glycol can be used. The organic solvent may be a polar solvent such as acetic acid, dimethyl-formamide (DMFO) or dimethyl sulfoxide (DMSO), acetonitrile, ethyl acetate, methyl acetate, fluoroalkane, pentane, 2,2,4-trimethylpentane, decane 1-pentene, 1-chlorobutane, 1-chloropentane, o-xylene, diisopropyl ether, 2-chloropropane, toluene, 1- chloropropane, chlorobenzene , Non-polar solvents such as benzene, diethyl ether, diethyl sulfide, chloroform, dichloromethane, 1,2-dichloroethane, aniline, diethylamine, ether, carbon tetrachloride and THF (tetrahydrofuran) may be used.
한 구체예에서, 상기 복분자유는 복분자씨를 헥산을 사용해 추출해 낸 것일 수 있다. In one embodiment, the brambly oil may be obtained by extracting brambly seed using hexane.
본 명세서에서 사용되는 복분자유는 복분자씨로부터 압착 또는 용매추출을 통해 얻은 조추출물뿐만 아니라 이의 가공물도 포함한다. The bramble oil used in the present specification includes not only the crude extract obtained from the bramble seeds by compression or solvent extraction but also the processed product thereof.
한편, 유산균은 세포벽에 존재하는 펩티도글리칸 성분으로 인해 면역증강 효능을 갖는 것으로 알려져 있다. 이에 본 발명자들은 복분자유와 복합하여 사용할 수 있는 면역증강 효능을 갖는 후보물질로 유산균을 선택하고 이를 동시투여한 효과에 대해 연구한 결과, 예기치 않게도 복분자유 단독의 면역증강 및/또는 갱년기증상 개선 활성에 비해 동시투여군에서의 면역증강 및/또는 갱년기증상 개선 활성이 현저히 높다는 사실을 발견하였다. On the other hand, lactic acid bacteria are known to have an immunostimulating effect due to a peptidoglycan component present in a cell wall. Therefore, the inventors of the present invention have conducted studies on the effect of selecting lactic acid bacteria as a candidate substance having immunity enhancing effect that can be used in combination with bokbunja oil and concurrently administering them. As a result, unexpectedly, The activity of improving immunity and / or improving menopausal symptoms in the co-administration group was significantly higher than that in the control group.
본 발명에서, 복분자유와 복합하여 사용되는 유산균은 생균 또는 사균일 수 있다. 한 구체예에서, 본 발명에서 사용될 수 있는 유산균은 사균일 수 있다. 사균 역시 펩티도글리칸 성분을 다량 함유하고 있을뿐만 아니라 사균을 사용할 경우 장내 전달시까지의 생존율 향상을 위한 코팅 등의 단계를 거칠 필요가 없으므로 많은 양의 유산균을 효과적으로 장내에 전달할 수 있게 되어 바람직하게 사용될 수 있다. In the present invention, the lactic acid bacterium to be used in combination with the bacterium oil may be a live bacterium or a bacterium. In one embodiment, the lactic acid bacteria that may be used in the present invention may be quaternary. The dead bacteria also contain a large amount of the peptidoglycan component, and when dead cells are used, it is not necessary to carry out a step such as a coating for improving the survival rate until intestinal transit, so that a large amount of lactic acid bacteria can be effectively delivered into the intestines Can be used.
본 발명에서 유산균은 유산균 또는 유산균 배양물로부터 얻은 균체 유래 성분, 이들의 동결건조물과 같은 가공물을 포함한다. In the present invention, lactic acid bacteria include components derived from a lactic acid bacterium or a lactic acid bacterium obtained from a culture, and processed products such as lyophilized products thereof.
일 구체예에서, 본 발명의 유산균은 락토바실러스 속(Lactobacillus sp .), 스포로락토바실러스 속(Sporolactobacilus sp .), 스트렙토코커스 속(Streptococcus sp .), 락토코커스 속(Lactococcus sp .), 루코노스톡 속(Leuconostoc sp .), 페디오코커스 속(Pedioococcus sp .), 엔테로코커스 속(Enterococcus sp .) 및 비피도박테리움 속(Bifidobacterium sp .)으로 이루어진 군으로부터 선택되는 하나 이상의 균주일 수 있다. In one embodiment, the lactic acid bacteria of the invention are selected from the group consisting of Lactobacillus sp . ), Spololactobacillus sp. ( Sporolactobacilus sp . ), The genus Streptococcus sp . ), The genus Lactococcus sp . ), Luconostoc genus ( Leuconostoc sp . ), The genus Pedioococcus ( Pedioococcus sp . ), Enterococcus ( Enterococcus sp . ) And Bifidobacterium sp . ). ≪ / RTI >
한편, 본 발명에 따른 복분자유 및 유산균을 포함하는 유효성분으로 포함하는 면역증강 및 갱년기증상 개선용 조성물은 약제학적 조성물 또는 식품 조성물로 활용될 수 있다.Meanwhile, the composition for improving immunity and improving menopausal symptoms, which comprises the bacterium oil and the lactic acid bacterium according to the present invention, may be used as a pharmaceutical composition or a food composition.
본 명세서에서 용어 ‘유효성분으로 포함하는’이란 복분자유 및/또는 유산균의 효능 또는 활성을 달성하는 데 충분한 양을 포함하는 것을 의미한다.As used herein, the term " comprising as an active ingredient " is meant to include an amount sufficient to achieve efficacy or activity of the botulinum and / or lactic acid bacteria.
본 발명의 한 구체예에서, 본 발명의 조성물 내에서 복분자유 및/또는 유산균은 예를 들어, 0.001 mg/kg 이상, 바람직하게는 0.1 mg/kg 이상, 보다 바람직하게는 10 mg/kg 이상, 보다 더 바람직하게는 100 mg/kg 이상, 보다 더욱 바람직하게는 250 mg/kg 이상, 가장 바람직하게는 0.1 g/kg 이상 포함된다.In one embodiment of the invention, the bacteriological oil and / or lactic acid bacteria in the composition of the present invention may be administered at a dose of, for example, 0.001 mg / kg or more, preferably 0.1 mg / kg or more, more preferably 10 mg / More preferably at least 100 mg / kg, even more preferably at least 250 mg / kg, most preferably at least 0.1 g / kg.
복분자유와 유산균은 식품으로서 허용되고 있는 성분들로서 과량 투여하여도 인체에 부작용이 없으므로 본 발명의 조성물 내에 포함되는 이들 성분의 양적 상한은 당업자가 적절한 범위 내에서 선택하여 실시할 수 있다.The bacterium oil and the lactic acid bacterium are ingredients that are allowed as foods, and even when administered in an excess amount, there is no adverse effect on the human body, so that the quantitative upper limit of these components contained in the composition of the present invention can be selected by a person skilled in the art within a suitable range.
본 발명의 약제학적 조성물은 상기 유효 성분 이외에 약제학적으로 적합하고 생리학적으로 허용되는 보조제를 사용하여 제조될 수 있으며, 상기 보조제로는 부형제, 붕해제, 감미제, 결합제, 피복제, 팽창제, 윤활제, 활택제 또는 향미제 등을 사용할 수 있다.The pharmaceutical composition of the present invention can be prepared by using pharmaceutically acceptable and physiologically acceptable adjuvants in addition to the above-mentioned active ingredients. Examples of the adjuvants include excipients, disintegrants, sweeteners, binders, coating agents, swelling agents, lubricants, A lubricant or a flavoring agent can be used.
상기 약제학적 조성물은 투여를 위해서 상기 기재한 유효 성분 이외에 추가로 약제학적으로 허용 가능한 담체를 1종 이상 포함하여 약제학적 조성물로 바람직하게 제제화할 수 있다. The pharmaceutical composition may be formulated into a pharmaceutical composition containing at least one pharmaceutically acceptable carrier in addition to the above-described active ingredients for administration.
상기 약제학적 조성물의 제제 형태는 과립제, 산제, 정제, 피복정, 캡슐제, 좌제, 액제, 시럽, 즙, 현탁제, 유제 등이 될 수 있다. 예를 들어, 정제 또는 캡슐제의 형태로의 제제화를 위해, 유효 성분은 에탄올, 글리세롤, 물 등과 같은 경구, 무독성의 약제학적으로 허용 가능한 불활성 담체와 결합될 수 있다. 또한, 원하거나 필요한 경우, 적합한 결합제, 윤활제, 붕해제 및 발색제 또한 혼합물로 포함될 수 있다. 적합한 결합제는 이에 제한되는 것은 아니나, 녹말, 젤라틴, 글루코스 또는 베타-락토오스와 같은 천연 당, 옥수수 감미제, 아카시아, 트래커캔스 또는 소듐올레이트와 같은 천연 및 합성 검, 소듐 스테아레이트, 마그네슘 스테아레이트, 소듐 벤조에이트, 소듐 아세테이트, 소듐 클로라이드 등을 포함한다. 붕해제는 이에 제한되는 것은 아니나, 녹말, 메틸 셀룰로스, 아가, 벤토니트, 잔탄 검 등을 포함한다. The pharmaceutical composition may be in the form of granules, powders, tablets, coated tablets, capsules, suppositories, liquids, syrups, juices, suspensions, emulsions and the like. For example, for formulation into tablets or capsules, the active ingredient may be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Also, if desired or necessary, suitable binders, lubricants, disintegrants and coloring agents may also be included as a mixture. Suitable binders include, but are not limited to, natural sugars such as starch, gelatin, glucose or beta-lactose, natural and synthetic gums such as corn sweeteners, acacia, tracker candles or sodium oleate, sodium stearate, magnesium stearate, sodium Benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.
더 나아가 해당분야의 적절한 방법으로 Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA에 개시되어 있는 방법을 이용하여 각 질환에 따라 또는 성분에 따라 바람직하게 제제화 할 수 있다. Further, it can be suitably formulated according to each disease or ingredient, using the method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA as an appropriate method in the field.
본 발명의 약제학적 조성물은 경구로 투여할 수 있다. 본 발명의 약제학적 조성물의 적합한 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하며, 보통으로 숙련된 의사는 소망하는 치료 또는 예방에 효과적인 투여량을 용이하게 결정 및 처방할 수 있다. 본 발명의 바람직한 구현예에 따르면, 본 발명의 약제학적 조성물의 1일 투여량은 0.001-10g/㎏이다.The pharmaceutical composition of the present invention can be administered orally. The appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as the formulation method, administration method, age, body weight, sex, pathological condition, food, administration time, administration route, excretion rate and responsiveness of the patient, Usually, a skilled physician can readily determine and prescribe dosages effective for the desired treatment or prophylaxis. According to a preferred embodiment of the present invention, the daily dosage of the pharmaceutical composition of the present invention is 0.001-10 g / kg.
본 발명의 약제학적 조성물은 당해 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있는 방법에 따라, 약제학적으로 허용되는 담체 및/또는 부형제를 이용하여 제제화 함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기 내에 내입시켜 제조될 수 있다. 이때 제형은 오일 또는 수성 매질중의 용액, 현탁액 또는 유화액 형태이거나 엑스제, 분말제, 과립제, 정제 또는 캅셀제 형태일 수도 있으며, 분산제 또는 안정화제를 추가적으로 포함할 수 있다.The pharmaceutical composition of the present invention may be formulated into a unit dose form by formulating it using a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by a person having ordinary skill in the art to which the present invention belongs. Or by intrusion into a multi-dose container. The formulations may be in the form of solutions, suspensions or emulsions in oils or aqueous media, or in the form of excipients, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents.
본 발명은 또한 복분자유 및 유산균을 유효성분으로 포함하는 면역증강 및 갱년기증상 개선용 식품조성물을 제공한다.The present invention also provides a food composition for improving immunity and improving menopausal symptoms comprising bacterium oil and lactic acid bacteria as an active ingredient.
본 발명에 따른 식품 조성물은 상기 약제학적 조성물과 동일한 방식으로 제제화되어 건강기능식품으로 이용하거나, 각종 식품에 첨가할 수 있다. 본 발명의 조성물을 첨가할 수 있는 식품으로는 예를 들어, 음료류, 알코올 음료류, 과자류, 다이어트바, 유제품, 육류, 초코렛, 피자, 라면, 기타 면류, 껌류, 아이스크림류, 비타민 복합제, 건강보조식품류 등이 있다.The food composition according to the present invention can be formulated in the same manner as the above pharmaceutical composition and used as a health functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, alcoholic beverages, confectioneries, diet bars, dairy products, meat, chocolates, pizza, ram noodles, other noodles, gums, ice cream, .
본 발명의 식품 조성물은 유효성분으로서 복분자유 및 유산균뿐만 아니라, 식품 제조 시에 통상적으로 첨가되는 성분을 포함할 수 있으며, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 포함한다. 상술한 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스, 올리고당 등; 및 폴리사카라이드, 예를 들어 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 향미제로서 천연 향미제 [타우마틴, 스테비아 추출물 (예를 들어 레바우디오시드 A, 글리시르히진 등]) 및 합성 향미제(사카린, 아스파르탐 등)를 사용할 수 있다. 예컨대, 본 발명의 식품 조성물이 드링크제와 음료류로 제조되는 경우에는 본 발명의 복분자유와 유산균 이외에 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 및 각종 식물 추출액 등을 추가로 포함시킬 수 있다.The food composition of the present invention may contain, as active ingredients, bacterium oils and lactic acid bacteria, as well as components that are ordinarily added during the manufacture of foods, including, for example, proteins, carbohydrates, fats, nutrients, seasonings and flavors do. Examples of the above-mentioned carbohydrates are monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavorings such as tau martin and stevia extract (e.g., rebaudioside A and glycyrrhizin) and synthetic flavorings (saccharine, aspartame, etc.) can be used as flavorings. For example, when the food composition of the present invention is prepared from a drink and a beverage, it may further include citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, juice, various plant extracts and the like in addition to the bokbunja oil and lactic acid bacteria of the present invention have.
본 발명은 상기 복분자유와 유산균을 유효성분으로 포함하는 면역증진 및 갱년기증상 개선용 식품 조성물을 포함하는 건강기능식품을 제공한다. 건강기능식품이란, 본 발명의 유효성분을 음료, 차류, 향신료, 껌, 과자류 등의 식품소재에 첨가하거나, 캡슐화, 분말화, 현탁액 등으로 제조한 식품으로, 이를 섭취할 경우 건강상 특정한 효과를 가져오는 것을 의미하나, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용시 발생할 수 있는 부작용 등이 없는 장점이 있다. 이와 같이 하여 얻어지는 본 발명의 건강기능식품은, 일상적으로 섭취하는 것이 가능하기 때문에 매우 유용하다. 이와 같은 건강기능식품에 있어서의 복분자유 및 유산균의 첨가량은, 대상인 건강기능식품의 종류에 따라 달라 일률적으로 규정할 수 없지만, 식품 본래의 맛을 손상시키지 않는 범위에서 첨가하면 되며, 대상 식품에 대하여 통상 0.01 내지 50 중량%, 바람직하기로는 0.1 내지 20 중량%의 범위이다. 또한, 액제, 환제, 과립제, 정제 또는 캡슐제 형태의 건강기능식품의 경우에는 통상 0.1 내지 100 중량% 바람직하기로는 0.5 내지 80 중량%의 범위에서 첨가하면 된다. 한 구체예에서, 본 발명의 건강기능식품은 액제, 캡슐제 또는 음료의 형태일 수 있다.The present invention provides a health functional food containing the bacterium oil and the lactic acid bacterium as an active ingredient and a food composition for improving immunity and improving menopausal symptoms. The health functional food is a food prepared by adding the active ingredient of the present invention to food materials such as beverage, tea, spice, gum and confectionery, or by encapsulation, powdering, suspension or the like, However, unlike general medicine, there is an advantage that there is no side effect that can occur when a food is used as a raw material for a long period of taking the medicine. The health functional food of the present invention thus obtained is very useful because it can be ingested routinely. The addition amount of the bacterium oil and the lactic acid bacterium in such a health functional food can not be uniformly determined depending on the kind of the health functional food to which it is added but may be added within a range that does not impair the original taste of the food, And usually ranges from 0.01 to 50% by weight, preferably from 0.1 to 20% by weight. In the case of a health functional food in the form of a liquid, a pill, a granule, a tablet or a capsule, it is usually added in an amount of 0.1 to 100% by weight, preferably 0.5 to 80% by weight. In one embodiment, the health functional food of the present invention may be in the form of a liquid, a capsule, or a drink.
본 발명은 또한 면역증진 및 갱년기증상 개선용 의약 또는 식품의 제조를 위한 상기 복분자유 및 유산균을 포함하는 복합 조성물의 용도를 제공한다. 상기한 바와 같이 복분자유 및 유산균을 포함하는 복합 조성물은 면역증강, 갱년기증상 개선을 위한 용도로 이용될 수 있다.The present invention also provides the use of a complex composition comprising the bacterium oil and the lactic acid bacterium for the manufacture of a medicament or food for improving immunity and improving menopausal symptoms. As described above, the complex composition comprising the bacterium oil and the lactic acid bacterium can be used for the purpose of improving immunity and improving the symptoms of menopausal symptoms.
또한 본 발명은 포유동물에게 유효량의 복분자유 및 유산균을 포함하는 복합 조성물을 투여하는 것을 포함하는 면역증강 또는 갱년기증상 개선 방법을 제공한다.The present invention also provides a method for improving immune enhancement or menopausal symptoms comprising administering to a mammal an effective amount of a complex composition comprising a bacterium oil and a lactic acid bacterium.
여기에서 사용된 용어 "포유동물"은 치료, 관찰 또는 실험의 대상인 포유동물을 말하며, 바람직하게는 인간을 말한다. The term "mammal " as used herein refers to a mammal that is the subject of treatment, observation or experimentation, preferably a human.
여기에서 사용된 용어 "유효량"은 연구자, 수의사, 의사 또는 기타 임상의에 의해 생각되는 조직계, 동물 또는 인간에서 생물학적 또는 의학적 반응을 유도하는 유효 성분 또는 약학적 조성물의 양을 의미하는 것으로, 이는 해당 질환 또는 장애의 증상의 완화를 유도하는 양을 포함한다. 본 발명의 유효 성분에 대한 유효량 및 투여횟수는 원하는 효과에 따라 변화될 것임은 당업자에게 자명하다. 그러므로, 투여될 최적의 투여량은 당업자에 의해 쉽게 결정될 수 있으며, 질환의 종류, 질환의 중증도, 조성물에 함유된 유효성분 및 다른 성분의 함량, 제형의 종류, 및 환자의 연령, 체중, 일반 건강 상태, 성별 및 식이, 투여 시간, 투여 경로 및 조성물의 분비율, 치료기간, 동시 사용되는 약물을 비롯한 다양한 인자에 따라 조절될 수 있다. 본 발명의 예방, 치료 또는 개선 방법에 있어서, 성인의 경우, 본 발명의 조성물을 1일 1회 내지 수회 투여시, 0.001 ㎎/kg 내지 10g/kg의 용량으로 투여하는 것이 바람직하다.
As used herein, the term "effective amount" refers to the amount of active ingredient or pharmaceutical composition that elicits a biological or medical response in a tissue system, animal, or human, as contemplated by a researcher, veterinarian, physician or other clinician, ≪ / RTI > inducing a reduction of the symptoms of the disease or disorder. It will be apparent to those skilled in the art that the effective amount and the administration frequency of the active ingredient of the present invention will vary depending on the desired effect. Thus, the optimal dosage to be administered can be readily determined by those skilled in the art and will vary with the nature of the disease, the severity of the disease, the amount of active and other ingredients contained in the composition, the type of formulation, and the age, The age, body weight, sex, diet, time of administration, route of administration and fraction of the composition, duration of treatment, concurrent medication, and the like. In the prevention, treatment, or improvement of the present invention, in the case of an adult, it is preferable to administer the composition of the present invention at a dose of 0.001 mg / kg to 10 g / kg once to several times a day.
본 발명에 따른 복분자유 및 유산균을 포함하는 복합 조성물은 위장내 유익균을 증가시킬뿐만 아니라, 면역증강 및 갱년기증상 개선의 효과를 제공한다. 또한, 버려지는 농식품 부산물인 복분자박을 이용하여 추출한 복분자유를 활용하기 때문에 식품소재로서 안전할 뿐만 아니라 제조상 경제적인 이점이 있다.
The complex composition comprising the bacterium oil and the lactic acid bacterium according to the present invention not only increases the intestinal beneficial bacteria but also provides the effect of enhancing the immune system and improving the symptoms of menopausal symptoms. In addition, since it uses bokbunja oil extracted from bokbunjae which is an abandoned agricultural product byproduct, it is safe as a food material and has an economical advantage in manufacturing.
[[ 실시예Example ]]
본 발명의 이점 및 특징, 그리고 그것들을 달성하는 방법은 상세하게 후술되어 있는 실시예들을 참조하면 명확해질 것이다. 그러나 본 발명은 이하에서 개시되는 실시예들에 한정되는 것이 아니라 서로 다른 다양한 형태로 구현될 것이며, 단지 본 실시예들은 본 발명의 개시가 완전하도록 하고, 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에게 발명의 범주를 완전하게 알려주기 위해 제공되는 것이며, 본 발명은 청구항의 범주에 의해 정의될 뿐이다.
Advantages and features of the present invention and methods of achieving them will become apparent with reference to the embodiments described in detail below. The present invention may, however, be embodied in many different forms and should not be construed as being limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art. Is provided to fully convey the scope of the invention to those skilled in the art, and the invention is only defined by the scope of the claims.
<실시예 1> ≪ Example 1 >
전라북도 고창지역에서 재배된 복분자 과실 (Rubus coreanum fruit) 1kg을 물 1kg에 넣고 상온에서 2시간 동안 1차 착즙하여 과즙을 120g 수득하였다. 1차 착즙 후의 잔사를 진액압착기에 넣고 압착하여 복분자 농축액을 40g 추가로 수득하였다. Bokbunja fruit grown in Gochang area, Jeollabuk-do ( Rubus coreanum fruit) was added to 1 kg of water and the juice was firstly squeezed at room temperature for 2 hours to obtain 120 g of juice. The residue after the first pouring was put into a vacuum press and compressed to obtain an additional 40 g of a brambly concentrate.
1차 착즙 후의 잔사 및 압착 후의 잔사를 모아 진공회전 농축기로 감압농축하여 용매 성분을 제거한 후, 열풍 건조시켜 복분자씨를 분리한 후 이를 체 진동기에 넣고 직경 0.1mm 체에 털어 분리하였으며, 이를 다시 원심분리기에 넣고 3000rpm에서 20분동안 원심분리하여 복분자씨만을 분리하였다 (70g).The residue after the first extraction and the residue after the compression were collected and concentrated under reduced pressure using a vacuum rotary condenser to remove solvent components and then hot air dried to separate the bacterium seeds. The bacterium seeds were removed by shaking in a 0.1 mm sieve, And centrifuged at 3000 rpm for 20 minutes to isolate only the brambled seed (70 g).
상기 수득된 복분자씨 70g을 착유기에 넣고 온압착유법을 실시하여 복분자유를 수득하였다 (12g).
70 g of the obtained bramble seeds were placed in a milking machine and subjected to a pressure-tight milking method to obtain a bramble oil (12 g).
Claims (12)
Wherein the composition comprises bacterium oil and lactic acid bacterium as an active ingredient.
상기 복분자유는 복분자씨로부터 온압착법에 의해 얻는 것인 면역증강용 식품 조성물.
The method according to claim 1,
Wherein the brambled oil is obtained by a pressing method from brambly seeds.
상기 복분자유는 복분자씨의 헥산 추출물인 면역증강용 식품 조성물.
The method according to claim 1,
Wherein the bramble oil is a hexane extract of bramble seeds.
싱기 유산균은 사균인 면역증강용 식품 조성물.
The method according to claim 1,
Wherein the Lactobacillus acidophilus is a deadly bacterium.
상기 유산균은 락토바실러스 속(Lactobacillus sp .), 스포로락토바실러스 속(Sporolactobacilus sp .), 스트렙토코커스 속(Streptococcus sp .), 락토코커스 속(Lactococcus sp .), 루코노스톡 속(Leuconostoc sp .), 페디오코커스 속(Pedioococcus sp .), 엔테로코커스 속(Enterococcus sp .) 및 비피도박테리움 속(Bifidobacterium sp .)으로 이루어진 군으로부터 선택되는 하나 이상의 균주인 면역증강용 식품 조성물.
The method according to claim 1,
The lactic acid bacteria may be selected from the group consisting of Lactobacillus sp . ), Spololactobacillus sp. ( Sporolactobacilus sp . ), The genus Streptococcus sp . ), The genus Lactococcus sp . ), Luconostoc genus ( Leuconostoc sp . ), The genus Pedioococcus ( Pedioococcus sp . ), Enterococcus ( Enterococcus sp . ) And Bifidobacterium sp . ). ≪ / RTI >
Wherein the composition contains baclofen oil and lactic acid bacterium as an active ingredient.
상기 복분자유는 복분자씨로부터 온압착법에 의해 얻는 것인 갱년기증상 개선용 식품 조성물.
The method according to claim 6,
Wherein the brambled oil is obtained by a pressing method from brambles seeds.
상기 복분자유는 복분자씨의 헥산 추출물인 갱년기증상 개선용 식품 조성물.
The method according to claim 6,
Wherein the bramble oil is a hexane extract of bramble seeds.
싱기 유산균은 사균인 갱년기증상 개선용 식품 조성물.
The method according to claim 6,
A composition for improving the symptoms of menopausal symptoms, wherein the Lactobacillus acidophilus is a deadly bacterium.
상기 유산균은 락토바실러스 속(Lactobacillus sp .), 스포로락토바실러스 속(Sporolactobacilus sp .), 스트렙토코커스 속(Streptococcus sp .), 락토코커스 속(Lactococcus sp .), 루코노스톡 속(Leuconostoc sp .), 페디오코커스 속(Pedioococcus sp .), 엔테로코커스 속(Enterococcus sp .) 및 비피도박테리움 속(Bifidobacterium sp .)으로 이루어진 군으로부터 선택되는 하나 이상의 균주인 갱년기증상 개선용 식품 조성물.The method according to claim 6,
The lactic acid bacteria may be selected from the group consisting of Lactobacillus sp . ), Spololactobacillus sp. ( Sporolactobacilus sp . ), The genus Streptococcus sp . ), The genus Lactococcus sp . ), Luconostoc genus ( Leuconostoc sp . ), The genus Pedioococcus ( Pedioococcus sp . ), Enterococcus ( Enterococcus sp . ) And Bifidobacterium sp . ). ≪ / RTI >
상기 식품 조성물은 여성 갱년기증상의 개선을 위한 것인 갱년기증상 개선용 식품 조성물.
The method according to claim 6,
Wherein the food composition is for improving female menopausal symptoms.
상기 식품 조성물은 남성 갱년기증상의 개선을 위한 것인 갱년기증상 개선용 식품 조성물.
The method according to claim 6,
Wherein the food composition is for the improvement of male menopausal symptoms.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140028276A KR20150106478A (en) | 2014-03-11 | 2014-03-11 | Extract of Black raspberry containing lactic acid bacterium for immunological enhancement and improving climacteric symptoms |
| PCT/KR2015/001462 WO2015137633A1 (en) | 2014-03-11 | 2015-02-13 | Composite extract of black raspberry oil, raspberry oil and mulberry oil |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140028276A KR20150106478A (en) | 2014-03-11 | 2014-03-11 | Extract of Black raspberry containing lactic acid bacterium for immunological enhancement and improving climacteric symptoms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20150106478A true KR20150106478A (en) | 2015-09-22 |
Family
ID=54245269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020140028276A Ceased KR20150106478A (en) | 2014-03-11 | 2014-03-11 | Extract of Black raspberry containing lactic acid bacterium for immunological enhancement and improving climacteric symptoms |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20150106478A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018030837A1 (en) * | 2016-08-12 | 2018-02-15 | 한국식품연구원 | Composition for preventing or treating menopause, containing lactobacillus acidophilus |
| US11260087B2 (en) | 2016-08-12 | 2022-03-01 | Korea Food Research Institute | Composition for preventing or treating menopause, containing Lactobacillus acidophilus |
| KR20250131880A (en) | 2024-02-27 | 2025-09-04 | (주) 에이투젠 | Composition containing Lacticaseibacillus paracasei strain for improving andropause |
| KR20250131882A (en) | 2024-02-27 | 2025-09-04 | (주) 에이투젠 | Composition containing Lactiplantibacillus plantarum strain for improving andropause |
| KR20250131884A (en) | 2024-02-27 | 2025-09-04 | (주) 에이투젠 | Composition containing Limosilactobacillus fermentum ATG-F11 strain for improving andropause |
| KR20250131886A (en) | 2024-02-27 | 2025-09-04 | (주) 에이투젠 | Composition containing Streptococcus thermophilus ATG-V11 strain for improving andropause |
-
2014
- 2014-03-11 KR KR1020140028276A patent/KR20150106478A/en not_active Ceased
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018030837A1 (en) * | 2016-08-12 | 2018-02-15 | 한국식품연구원 | Composition for preventing or treating menopause, containing lactobacillus acidophilus |
| US11260087B2 (en) | 2016-08-12 | 2022-03-01 | Korea Food Research Institute | Composition for preventing or treating menopause, containing Lactobacillus acidophilus |
| KR20250131880A (en) | 2024-02-27 | 2025-09-04 | (주) 에이투젠 | Composition containing Lacticaseibacillus paracasei strain for improving andropause |
| KR20250131882A (en) | 2024-02-27 | 2025-09-04 | (주) 에이투젠 | Composition containing Lactiplantibacillus plantarum strain for improving andropause |
| KR20250131884A (en) | 2024-02-27 | 2025-09-04 | (주) 에이투젠 | Composition containing Limosilactobacillus fermentum ATG-F11 strain for improving andropause |
| KR20250131886A (en) | 2024-02-27 | 2025-09-04 | (주) 에이투젠 | Composition containing Streptococcus thermophilus ATG-V11 strain for improving andropause |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102171001B1 (en) | Method of Aronia extract having improved Anthocyanin content and Anti-obesity effect, and extract of the same | |
| KR20150106478A (en) | Extract of Black raspberry containing lactic acid bacterium for immunological enhancement and improving climacteric symptoms | |
| TWI648057B (en) | Composition for relieving premenstrual syndrome and menstrual pain | |
| EP2083838B1 (en) | Medicinal herbal extract having anti-obesity effect | |
| JP2022009308A (en) | Composition for ameliorating climacteric symptoms or osteoporosis | |
| KR102236685B1 (en) | Composition for preventing or treating lipid metabolism diseases comprising extract of salvia miltiorrhiza or paeonia lactiflora | |
| KR20150113434A (en) | A composition comprising the extract of ginseng seed for protecting brain cells and preventing, improving and treating depression | |
| WO2006001654A1 (en) | Composition containing ginseng extract comprising saponin derivatives isolated fromginseng radix and ginseng for preventing and treating scratching diseases | |
| JP2015182987A (en) | Anti-inflammatory agent | |
| KR102157048B1 (en) | Composition for preventing or improving non-alcoholic fatty liver disease comprising complex extracts of ginger, centella asiatica and ramie leaf | |
| KR20150031373A (en) | Phamaceutical and food composition for preventing or treating obesity comprising extract of leaf from Hoppophea rhamnoids as effective component | |
| JP2024050702A (en) | Composition for preventing or treating obesity or obesity-induced metabolic syndrome, comprising Enterococcus faecalis as an active ingredient | |
| KR101828167B1 (en) | Composition for anti-obesity comprising the extract of aronia and method for preparing thereof | |
| KR102014922B1 (en) | Composition for improving digestive functions comprising glabridin from Liquorice | |
| KR101760163B1 (en) | Composition for anti-obesity comprising extract of Sargassum serratifolium as an effective component | |
| KR20160047055A (en) | Extract of black raspberry, raspberry and mulberry | |
| CN107432889A (en) | Menopause symptom or osteoporosis improvement composition | |
| KR20110078237A (en) | Obesity treatment or prevention composition containing loquat extract | |
| CN105816508A (en) | Use of small black soybean extract in preparation of composition for prevention, improvement or treatment of retinal diseases | |
| KR101904819B1 (en) | Composition comprising Fermented Momordica charantia L. and Allium sativum L. using Amyloliquefaciens Bacillus Jis-1 for lowering blood glucose or preventing and treating diabetes mellitus | |
| KR102427768B1 (en) | Composition containing the extracts or fractions of Agastache rugosa for the prevention and treatment of postmenopausal syndrome | |
| KR20130029283A (en) | Composition for constipation | |
| KR101580209B1 (en) | Compositions Comprising an Extract of Oenanthe javanica DC for the Prevention and Treatment of Immuno-deficiency disease | |
| KR101801130B1 (en) | A Composition Comprising the combined herbal extract for preventing or improving the hormonal abnormal syndrome in women | |
| JP2016060736A (en) | Glucose metabolism improver |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20140311 |
|
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 20150507 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20190311 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20140311 Comment text: Patent Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20200523 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20200824 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20200523 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |